Core Insights - On August 13, Weisi Medical's stock closed at 56.00 yuan, an increase of 0.14 yuan, representing a 0.25% rise [1] - The trading volume for the day was 48,657 hands, with a transaction amount of 270 million yuan, resulting in a turnover rate of 5.08% [1] - Weisi Medical operates in the medical device sector, focusing on the research, production, and sales of medical equipment, including rehabilitation medical devices and surgical instruments [1] Financial Performance - On August 13, the net outflow of main funds for Weisi Medical was 14.5931 million yuan, with a cumulative net outflow of 8.8830 million yuan over the past five days [1] - The overall performance of the medical device sector on that day was poor, with several related stocks experiencing declines [1]

Group 1 - The core stock price of Xiangyu Medical as of August 6, 2025, is 52.80 yuan, reflecting a decrease of 1.18% from the previous trading day, with a trading volume of 294 million yuan and a turnover rate of 3.48% [1] - Xiangyu Medical operates in the medical device sector, focusing on the research, production, and sales of rehabilitation medical equipment, providing comprehensive rehabilitation solutions for medical institutions [1] - The company is actively advancing the integration of its self-developed brain-computer interface products with its rehabilitation equipment, aiming to create a complete brain-computer interface solution and gradually promote it to various levels of medical institutions [1] Group 2 - Currently, related products are undergoing clinical trials at multiple centers to verify their effectiveness compared to traditional rehabilitation methods [1] - On August 6, the net outflow of main funds for Xiangyu Medical was 17.81 million yuan, with a cumulative net outflow of 34.79 million yuan over the past five days [1]

翔宇医疗属于医疗器械板块，公司主营业务为医疗器械的研发、生产和销售。公司产品涵盖多个医疗领 域，包括康复医疗设备等。 截至2025年7月31日收盘，翔宇医疗股价报46.00元，较前一交易日下跌0.55元，跌幅1.18%。当日成交 量为49334手，成交金额达2.27亿元。 来源:金融界 风险提示：股市有风险，投资需谨慎。 从资金流向来看，翔宇医疗7月31日主力资金净流出2320.53万元，占流通市值的0.32%。近期医疗器械 行业受到政策关注，国家医保局新设多项医疗新技术相关价格项目，包括脑机接口等创新技术。 ...